unresectable primary hepatocellular carcinoma
Conditions
Interventions
Training cohort and Validation cohort:None
Sponsors
Xiangyang Central Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.clinical or histopathological diagnosis of HCC; 2.patients received immune checkpoint inhibitors plus anti-angiogenic targeted therapy with or without interventional therapy as first line treatment for initial diagnosis; 3.patients performed liver computed tomography plain scan within one month prior to initial therapy and at least one measurable target lesion was available for the tumor response evaluation; 4.The follow-up of the retrospective study is not interrupted and clinical datas are complete.
Exclusion criteria
Exclusion criteria: 1.histopathological diagnosis was other pathological types,such as cholangiocarcinoma,neuroendocrine carcinoma and so on; 2.a combination of other malignant cancers; 3.patients received other therapies for liver tumors except immune checkpoint inhibitors,anti-angiogenic targeted therapy and interventional therapy,such as radiotherapy and surgical resection; 4.lack of clinical datas.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Therapeutic evaluation; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression-Free Survival(PFS);Overall Survival(OS); | — |
Countries
China
Contacts
Public ContactLi Yong
Xiangyang Central Hospital
Outcome results
None listed